Degradable polymeric vehicles for postoperative pain management.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
29
06
2020
accepted:
20
01
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
10
3
2021
Statut:
epublish
Résumé
Effective control of pain management has the potential to significantly decrease the need for prescription opioids following a surgical procedure. While extended release products for pain management are available commercially, the implementation of a device that safely and reliably provides extended analgesia and is sufficiently flexible to facilitate a diverse array of release profiles would serve to advance patient comfort, quality of care and compliance following surgical procedures. Herein, we review current polymeric systems that could be utilized in new, controlled post-operative pain management devices and highlight where opportunities for improvement exist.
Identifiants
pubmed: 33649338
doi: 10.1038/s41467-021-21438-3
pii: 10.1038/s41467-021-21438-3
pmc: PMC7921139
doi:
Substances chimiques
Analgesics
0
Polymers
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1367Références
Mathiesen, O., Thomsen, B., Kitter, B., Dahl, J. & Kehlet, H. Need for improved treatment of postoperative pain. Dan. Med. J. 59, A4401 (2012).
pubmed: 22459715
Apfelbaum, J. L., Chen, C., Mehta, S. S. & Gan, T. J. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth. Analg. 97, 534–540 (2003).
pubmed: 12873949
doi: 10.1213/01.ANE.0000068822.10113.9E
Gan, T. J., Habib, A. S., Miller, T. E., White, W. & Apfelbaum, J. L. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr. Med. Res. Opin. 30, 149–160 (2014).
pubmed: 24237004
doi: 10.1185/03007995.2013.860019
Bartels, K. et al. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS ONE 11, e0147972 (2016).
pubmed: 26824844
pmcid: 4732746
doi: 10.1371/journal.pone.0147972
Mason, M. J. et al. Depression moderates the relationship between pain and the nonmedical use of opioid medication among adult outpatients. J. Addict. Med. 10, 408–413 (2016).
pubmed: 27559846
doi: 10.1097/ADM.0000000000000253
Leppert, W., Malec-Milewska, M., Zajaczkowska, R. & Wordliczek, J. Transdermal and topical drug administration in the treatment of pain. Molecules 23, 681 (2018).
pmcid: 6017304
doi: 10.3390/molecules23030681
Guay, J. & Kopp, S. Epidural pain relief versus systemic opioid‐based pain relief for abdominal aortic surgery. Cochrane Database Syst. Rev. 2016, CD005059 (2016).
Ji, R. R., Chamessian, A. & Zhang, Y. Q. Pain regulation by non-neuronal cells and inflammation. Science 354, 572–577 (2016).
pubmed: 27811267
pmcid: 5488328
doi: 10.1126/science.aaf8924
Kehlet, H., Jensen, T. S. & Woolf, C. J. Persistent postsurgical pain: risk factors and prevention. Lancet 367, 1618–1625 (2006).
pubmed: 16698416
doi: 10.1016/S0140-6736(06)68700-X
Chi-Fei Wang, J., Hung, C. H., Gerner, P., Ji, R. R. & Strichartz, G. R. The qualitative hyperalgesia profile: a new metric to assess chronic post-thoracotomy. Pain. Open Pain. J. 6, 190–198 (2013).
pubmed: 24567767
doi: 10.2174/1876386301306010190
Matsuda, M., Huh, Y. & Ji, R. R. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J. Anesth. 33, 131–139 (2019).
pubmed: 30448975
doi: 10.1007/s00540-018-2579-4
Gold, M. S. & Gebhart, G. F. Nociceptor sensitization in pain pathogenesis. Nat. Med. 16, 1248–1257 (2010).
pubmed: 20948530
pmcid: 5022111
doi: 10.1038/nm.2235
Ji, R. R., Kohno, T., Moore, K. A. & Woolf, C. J. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 26, 696–705 (2003).
pubmed: 14624855
doi: 10.1016/j.tins.2003.09.017
Price, T. J. et al. Transition to chronic pain: opportunities for novel therapeutics. Nat. Rev. Neurosci. 19, 383–384 (2018).
Ji, R. R., Berta, T. & Nedergaard, M. Glia and pain: is chronic pain a gliopathy? Pain 154 Supplement 1, S10-S28. https://doi.org/10.1016/j.pain.2013.06.022 (2013).
Inoue, K. & Tsuda, M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat. Rev. Neurosci. 19, 138–152 (2018).
pubmed: 29416128
doi: 10.1038/nrn.2018.2
Kehlet, H. & Dahl, J. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 362, 1921–1928 (2004).
doi: 10.1016/S0140-6736(03)14966-5
Bulut, T., Yilmazlar, A., Yavascaoglu, B. & Sarisozen, B. The effect of local anaesthetic on post-operative pain with wound instillation via a catheter for paediatric orthopaedic extremity surgery. J. Child Orthop. 5, 179–185 (2011).
pubmed: 22654979
pmcid: 3100459
doi: 10.1007/s11832-011-0337-3
Garimella, V. & Cellini, C. Postoperative pain control. Clin. Colon Rectal Surg. 26, 191–196 (2013).
pubmed: 24436674
pmcid: 3747287
doi: 10.1055/s-0033-1351138
Vadivelu, N., Mitra, S. & Narayan, D. Recent advances in postoperative pain management. Yale J. Biol. Med. 83, 11–25 (2010).
pubmed: 20351978
pmcid: 2844689
Corder, G., Castro, D. C., Bruchas, M. R. & Scherrer, G. Endogenous and exogenous opioids in pain. Annu. Rev. Neurosci. 41, 453–473 (2018).
Stein, C. & Lang, L. J. Peripheral mechanisms of opioid analgesia. Curr. Opin. Pharmacol. 9, 3–8 (2009).
pubmed: 19157985
doi: 10.1016/j.coph.2008.12.009
Ji, R. R. et al. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J. Neurosci. 15, 8156–8166 (1995).
pubmed: 8613750
pmcid: 6577939
doi: 10.1523/JNEUROSCI.15-12-08156.1995
Millan, M. J. Multiple opioid systems and pain. Pain 27, 303–347 (1986).
pubmed: 3027643
doi: 10.1016/0304-3959(86)90158-2
Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819–823 (1996).
pubmed: 8893006
doi: 10.1038/383819a0
McCorvy, J. D. et al. Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs. Nat. Chem. Biol. 14, 126–134 (2018).
pubmed: 29227473
doi: 10.1038/nchembio.2527
Martyn, J. A. J., Mao, J. & Bittner, E. A. Opioid tolerance in critical illness. N. Engl. J. Med. 380, 365–378 (2019).
pubmed: 30673555
pmcid: 6897318
doi: 10.1056/NEJMra1800222
Mao, J. Clinical Diagnosis of opioid-induced hyperalgesia. Reg. Anesth. Pain. Med. 40, 663–664 (2015).
pubmed: 26488079
doi: 10.1097/AAP.0000000000000317
Aneizi, A. et al. Impact of preoperative opioid use on 2-year patient-reported outcomes in knee surgery patients. J. Knee Surg. https://doi.org/10.1055/s-0040-1716358 (2020).
Volkow, N. D. & Collins, F. S. The role of science in addressing the opioid crisis. N. Engl. J. Med. 377, 391–394 (2017).
pubmed: 28564549
doi: 10.1056/NEJMsr1706626
Culp, W. C. & Culp, W. C. Practical application of local anesthetics. J. Vasc. Interv. Radiol. 22, 111–118 (2011).
pubmed: 21146999
doi: 10.1016/j.jvir.2010.10.005
Peskin, R. M. Handbook of local anesthesia. N. Y. State Dent. J. 71, 76–77 (2005).
Waxman, S. G., Dib-Hajj, S., Cummins, T. R. & Black, J. A. Sodium channels and pain. Proc. Natl Acad. Sci. USA 96, 7635–7639 (1999).
pubmed: 10393872
doi: 10.1073/pnas.96.14.7635
pmcid: 33593
Bennett, D. L. & Woods, C. G. Painful and painless channelopathies. Lancet Neurol. 13, 587–599 (2014).
pubmed: 24813307
doi: 10.1016/S1474-4422(14)70024-9
Roberge, C. W. & McEwen, M. The effects of local anesthetics on postoperative pain. Aorn j. 68, 1003–1012 (1998).
pubmed: 9864591
doi: 10.1016/S0001-2092(06)62134-0
Becker, D. E. & Reed, K. L. Local anesthetics: review of pharmacological considerations. Anesth. Prog. 59, 90–101 (2012). quiz 102-103.
pubmed: 22822998
pmcid: 3403589
doi: 10.2344/0003-3006-59.2.90
Binshtok, A. M., Bean, B. P. & Woolf, C. J. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature 449, 607–610 (2007).
pubmed: 17914397
doi: 10.1038/nature06191
Xu, Z. Z. et al. Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade. Nat. Med. 21, 1326–1331 (2015).
pubmed: 26479925
pmcid: 4752254
doi: 10.1038/nm.3978
Gold, M. S., Levine, J. D. & Correa, A. M. Modulation of TTX-R INa by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in vitro. J. Neurosci. 18, 10345–10355 (1998).
pubmed: 9852572
pmcid: 6793376
doi: 10.1523/JNEUROSCI.18-24-10345.1998
Aley, K. O. & Levine, J. D. Role of protein kinase A in the maintenance of inflammatory pain. J. Neurosci. 19, 2181–2186 (1999).
pubmed: 10066271
pmcid: 6782560
doi: 10.1523/JNEUROSCI.19-06-02181.1999
St-Jacques, B. & Ma, W. Prostaglandin E2/EP4 signalling facilitates EP4 receptor externalization in primary sensory neurons in vitro and in vivo. Pain 154, 313–323 (2013).
pubmed: 23265688
doi: 10.1016/j.pain.2012.11.005
Reichling, D. B. & Levine, J. D. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 32, 611–618 (2009).
pubmed: 19781793
pmcid: 2787756
doi: 10.1016/j.tins.2009.07.007
Choi, S.-H., Aid, S. & Bosetti, F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci. 30, 174–181 (2009).
pubmed: 19269697
pmcid: 3379810
doi: 10.1016/j.tips.2009.01.002
Samad, T. A. et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410, 471–475 (2001).
pubmed: 11260714
doi: 10.1038/35068566
Fuenmayor, E. et al. Comparison of fused-filament fabrication to direct compression and injection molding in the manufacture of oral tablets. Int. J. Pharm. 558, 328–340 (2019).
pubmed: 30659922
doi: 10.1016/j.ijpharm.2019.01.013
Fuenmayor, E. et al. Mass-customization of oral tablets via the combination of 3D printing and injection molding. Int. J. Pharm. 569, 118611 (2019).
pubmed: 31415874
doi: 10.1016/j.ijpharm.2019.118611
Pandey, M. et al. 3D printing for oral drug delivery: a new tool to customize drug delivery. Drug Deliv. Transl. Res. 10, 986–1001 (2020).
Xu, X., Zhao, J., Wang, M., Wang, L. & Yang, J. 3D printed polyvinyl alcohol tablets with multiple release profiles. Sci. Rep. 9, 12487 (2019).
pubmed: 31462744
pmcid: 6713737
doi: 10.1038/s41598-019-48921-8
Repka, M. A., Majumdar, S., Kumar Battu, S., Srirangam, R. & Upadhye, S. B. Applications of hot-melt extrusion for drug delivery. Expert Opin. Drug Deliv. 5, 1357–1376 (2008).
pubmed: 19040397
pmcid: 5821067
doi: 10.1517/17425240802583421
Alshetaili, A. S. et al. Preparation and evaluation of hot-melt extruded patient-centric ketoprofen mini-tablets. Curr. Drug Deliv. 13, 730–741 (2016).
pubmed: 26456211
pmcid: 6062439
doi: 10.2174/1567201812666151012113806
Al-Hashimi, N., Begg, N., Alany, R. G., Hassanin, H. & Elshaer, A. Oral modified release multiple-unit particulate systems: compressed pellets, microparticles and nanoparticles. Pharmaceutics 10, 176 (2018).
pmcid: 6321440
doi: 10.3390/pharmaceutics10040176
Portenoy, R. K. et al. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J. Pain. Symptom Manag. 23, 292–300 (2002).
doi: 10.1016/S0885-3924(02)00382-2
Wilson, C. G. in Biomaterials Science 3rd edn, (eds Ratner, B., Hoffman, A., Schoen, F. & Lemons, J. E.) 1083–1087 (Academic Press, 2013).
Pond, S. M. & Tozer, T. N. First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. 9, 1–25 (1984).
pubmed: 6362950
doi: 10.2165/00003088-198409010-00001
Candiotti, K. Liposomal bupivacaine: an innovative nonopioid local analgesic for the management of postsurgical pain. Pharmacotherapy 32, 19S–26S (2012).
pubmed: 22956491
doi: 10.1002/j.1875-9114.2012.01183.x
Gambling, D., Hughes, T., Martin, G., Horton, W. & Manvelian, G. A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg. 100, 1065–1074 (2005).
Sharpe, L. et al. PH-responsive microencapsulation systems for the oral delivery of polyanhydride nanoparticles. Biomacromolecules 19, 793–802 (2018).
pubmed: 29443509
pmcid: 6103212
doi: 10.1021/acs.biomac.7b01590
Janssen, M. et al. Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. J. Control Release 244, 30–40 (2016).
pubmed: 27836707
doi: 10.1016/j.jconrel.2016.11.003
Kim, D. K. & Dobson, J. Nanomedicine for targeted drug delivery. J. Mater. Chem. 19, 6294–6307 (2009).
doi: 10.1039/b902711b
Galer, B. S., Rowbotham, M. C., Perander, J. & Friedman, E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80, 533–538 (1999).
pubmed: 10342414
doi: 10.1016/S0304-3959(98)00244-9
Blair, H. A. Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. Drugs 78, 1489–1500 (2018).
pubmed: 30251173
doi: 10.1007/s40265-018-0982-7
Food and Drug Administration. Fentanyl Transdermal System (marketed as Duragesic and generics). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fentanyl-transdermal-system-marketed-duragesic-information (2015).
Oliashirazi, A., Wilson-Byrne, T., Shuler, F. D. & Parvizi, J. Patient-controlled fentanyl iontophoretic transdermal system improved postoperative mobility compared to intravenous patient-controlled analgesia morphine: a pooled analysis of randomized, controlled trials. Pain. Pract. 17, 197–207 (2017).
pubmed: 27206564
doi: 10.1111/papr.12432
Soto, F. et al. Noninvasive transdermal delivery system of lidocaine using an acoustic droplet-vaporization based wearable patch. Small 14, e1803266 (2018).
pubmed: 30369022
doi: 10.1002/smll.201803266
Margetts, L. & Sawyer, R. Transdermal drug delivery: principles and opioid therapy. Continuing Educ. Anaesth. Crit. Care Pain. 7, 171–176 (2007).
doi: 10.1093/bjaceaccp/mkm033
Endo Pharmaceuticals Inc. LIDODERM (Lidocaine Patch 5%) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020612s012lbl.pdf (2015).
Stewart, S. A., Domínguez-Robles, J., Donnelly, R. F. & Larrañeta, E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers 10, 1379 (2018).
pmcid: 6401754
doi: 10.3390/polym10121379
Stoddard, A., McNicholas, C. & Peipert, J. F. Efficacy and safety of long-acting reversible contraception. Drugs 71, 969–980 (2011).
pubmed: 21668037
pmcid: 3662967
doi: 10.2165/11591290-000000000-00000
Hoy, S. M. & Keating, G. M. Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. Drugs 68, 1711–1721 (2008).
pubmed: 18681493
doi: 10.2165/00003495-200868120-00008
Dankiewicz, E. H. Use of the low-dose buprenorphine patch: a response. J. Palliat. Med. 17, 379–380 (2014).
pubmed: 24628132
pmcid: 3991960
doi: 10.1089/jpm.2014.9438
Pacira Biosciences, I. Non-Opioid Exparel, https://www.exparel.com/patient/non-opioid-pain-medication (2020).
Pacira Biosciences, I. FDA Advisory Committee Meeting Briefing Document: EXPAREL® (bupivacaine liposome injectable suspension). Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee. https://www.fda.gov/media/111001/download (2018).
Richard, B. M. et al. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin. Investig. Drugs 20, 1327–1341 (2011).
pubmed: 21867476
doi: 10.1517/13543784.2011.611499
Davidson, E. M. et al. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth. Analg. 110, 1018–1023 (2010).
pubmed: 20357145
doi: 10.1213/ANE.0b013e3181d26d2a
Chahar, P. & Cummings, K. C. 3rd Liposomal bupivacaine: a review of a new bupivacaine formulation. J. Pain. Res. 5, 257–264 (2012).
pubmed: 23049275
pmcid: 3442744
Malige, A., Yeazell, S., Ng-Pellegrino, A. & Carolan, G. Risk factors for complications and return to the emergency department after interscalene block using liposomal bupivacaine for shoulder surgery. J Shoulder Elbow Surg. (2020).
Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559–587 (2018).
pubmed: 29700501
doi: 10.1038/nrd.2018.46
Spahn, V. et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science 355, 966–969 (2017).
pubmed: 28254944
doi: 10.1126/science.aai8636
Ji, R. R., Xu, Z. Z., Wang, X. & Lo, E. H. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol. Sci. 30, 336–340 (2009).
pubmed: 19523695
pmcid: 2706286
doi: 10.1016/j.tips.2009.04.002
Martinez, P. R., Goyanes, A., Basit, A. W. & Gaisford, S. Influence of geometry on the drug release profiles of stereolithographic (SLA) 3D-printed tablets. AAPS PharmSciTech 19, 3355–3361 (2018).
pubmed: 29948979
doi: 10.1208/s12249-018-1075-3
Patra, J. K. et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnology 16, 71 (2018).
pubmed: 30231877
pmcid: 6145203
doi: 10.1186/s12951-018-0392-8
Maitz, M. F. Applications of synthetic polymers in clinical medicine. Biosurf. Biotribol. 1, 161–176 (2015).
doi: 10.1016/j.bsbt.2015.08.002
Langer, R. & Tirrell, D. A. Designing materials for biology and medicine. Nature 428, 487–492 (2004).
pubmed: 15057821
doi: 10.1038/nature02388
Göpferich, A. Mechanisms of polymer degradation and erosion. Biomaterials 17, 103–114 (1996).
pubmed: 8624387
doi: 10.1016/0142-9612(96)85755-3
Tamada, J. & Langer, R. The development of polyanhydrides for drug delivery applications. J. Biomater. Sci. Polym. Ed. 3, 315–353 (1992).
pubmed: 1350734
doi: 10.1163/156856292X00402
Barr, J., Woodburn, K. W., Ng, S. Y., Shen, H. R. & Heller, J. Post surgical pain management with poly(ortho esters). Adv. Drug Deliv. Rev. 54, 1041–1048 (2002).
pubmed: 12384320
doi: 10.1016/S0169-409X(02)00056-X
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S. & Shakesheff, K. M. Polymeric systems for controlled drug release. Chem. Rev. 99, 3181–3198 (1999).
pubmed: 11749514
doi: 10.1021/cr940351u
Song, R. et al. Current development of biodegradable polymeric materials for biomedical applications. Drug Des. Devel Ther. 12, 3117–3145 (2018).
pubmed: 30288019
pmcid: 6161720
doi: 10.2147/DDDT.S165440
Gianolio, D. A. et al. Hyaluronan-tethered opioid depots: synthetic strategies and release kinetics in vitro and in vivo. Bioconjug. Chem. 19, 1767–1774 (2008).
pubmed: 18717537
doi: 10.1021/bc8000479
Leiman, D., Niebler, G. & Minkowitz, H. S. Pharmacokinetics and safety of INL-001 (Bupivacaine HCl) implants compared with bupivacaine HCl infiltration after open unilateral inguinal hernioplasty. Adv. Ther. 1, 691–706 (2020).
Velanovich, V. et al. Safety and efficacy of bupivacaine HCl collagen-matrix implant (INL-001) in open inguinal hernia repair: results from two randomized controlled trials. Adv. Ther. 36, 200–216 (2019).
pubmed: 30467808
doi: 10.1007/s12325-018-0836-4
Langer, R. Polymer implants for drug delivery in the brain. J. Control. Release 16, 53–59 (1991).
doi: 10.1016/0168-3659(91)90030-H
Leong, K. W., Kost, J., Mathiowitz, E. & Langer, R. Polyanhydrides for controlled release of bioactive agents. Biomaterials 7, 364–371 (1986).
pubmed: 3778996
doi: 10.1016/0142-9612(86)90007-4
Rosen, H. B., Chang, J., Wnek, G. E., Linhardt, R. J. & Langer, R. Bioerodible polyanhydrides for controlled drug delivery. Biomaterials 4, 131–133 (1983).
pubmed: 6860755
doi: 10.1016/0142-9612(83)90054-6
Kipper, M. J., Shen, E., Determan, A. & Narasimhan, B. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials 23, 4405–4412 (2002).
pubmed: 12219831
doi: 10.1016/S0142-9612(02)00181-3
Stephens, D. et al. Investigation of the in vitro release of gentamicin from a polyanhydride matrix. J. Control. Release 63, 305–317 (2000).
pubmed: 10601726
doi: 10.1016/S0168-3659(99)00205-9
Li, L., Deng, J. & Stephens, D. Polyanhydride implant for antibiotic delivery—from the bench to the clinic. Adv. Drug Deliv. Rev. 54, 963–986 (2002).
pubmed: 12384317
doi: 10.1016/S0169-409X(02)00053-4
Torres, M. P., Determan, A. S., Anderson, G. L., Mallapragada, S. K. & Narasimhan, B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 28, 108–116 (2007).
pubmed: 16965812
doi: 10.1016/j.biomaterials.2006.08.047
Liu, X., Pettway, G. J., McCauley, L. K. & Ma, P. X. Pulsatile release of parathyroid hormone from an implantable delivery system. Biomaterials 28, 4124–4131 (2007).
pubmed: 17576005
pmcid: 2048537
doi: 10.1016/j.biomaterials.2007.05.034
Dang, M., Koh, A. J., Jin, X., McCauley, L. K. & Ma, P. X. Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold. Biomaterials 114, 1–9 (2017).
pubmed: 27835763
doi: 10.1016/j.biomaterials.2016.10.049
Wang, J. et al. Redox-responsive polyanhydride micelles for cancer therapy. Biomaterials 35, 3080–3090 (2014).
pubmed: 24388799
doi: 10.1016/j.biomaterials.2013.12.025
Berrada, M., Yang, Z. & Lehnert, S. Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments. Int. J. Radiat. Oncol. Biol. Phys. 54, 1550–1557 (2002).
pubmed: 12459384
doi: 10.1016/S0360-3016(02)03740-9
Storm, P. B. et al. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J. Neurooncol. 56, 209–217 (2002).
pubmed: 12061726
doi: 10.1023/A:1015003232713
Sipos, E., Tyler, B., Piantadosi, S., Burger, P. & Brem, H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol. 39, 383–389 (1997).
pubmed: 9054951
doi: 10.1007/s002800050588
Vogel, B. M. & Mallapragada, S. K. Synthesis of novel biodegradable polyanhydrides containing aromatic and glycol functionality for tailoring of hydrophilicity in controlled drug delivery devices. Biomaterials 26, 721–728 (2005).
pubmed: 15350776
doi: 10.1016/j.biomaterials.2004.03.024
Maniar, M., Domb, A., Haffer, A. & Shah, J. Controlled release of a local anesthetic from fatty acid dimer based polyanhydride. J. Control. Release 30, 233–239 (1994).
doi: 10.1016/0168-3659(94)90029-9
Park, E.-S., Maniar, M. & Shah, J. C. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation, and kinetics and mechanism of in vitro release. J. Control. Release 52, 179–189 (1998).
pubmed: 9685948
doi: 10.1016/S0168-3659(97)00223-X
Ulery, B. D. et al. Facile fabrication of polyanhydride/anesthetic nanoparticles with tunable release kinetics. Adv. Healthc. Mater. 3, 843–847 (2014).
pubmed: 24376136
doi: 10.1002/adhm.201300521
Heller, J. Development of poly(ortho esters): a historical overview. Biomaterials 11, 659–665 (1990).
pubmed: 2090300
doi: 10.1016/0142-9612(90)90024-K
Heller, J., Penhale, D. W. H. & Helwing, R. F. Preparation of poly(ortho esters) by the reaction of diketene acetals and polyols. J. Polym. Sci. Polym. Lett. Ed. 18, 619–624 (1980).
doi: 10.1002/pol.1980.130180907
Heller, J. & Barr, J. Poly(ortho esters) from concept to reality †. Biomacromolecules 5, 1625–1632 (2004).
pubmed: 15360265
doi: 10.1021/bm040049n
Ng, S. Y. et al. Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery. J. Control. Release 65, 367–374 (2000).
pubmed: 10699295
doi: 10.1016/S0168-3659(99)00218-7
Rothen-Weinhold, A. et al. Release of BSA from poly(ortho ester) extruded thin strands. J. Control. Release. 71, 31–37 (2001).
pubmed: 11245906
doi: 10.1016/S0168-3659(00)00348-5
Ulery, B. D., Nair, L. S. & Laurencin, C. T. Biomedical applications of biodegradable polymers. J. Polym. Sci. B Polym. Phys. 49, 832–864 (2011).
pubmed: 21769165
pmcid: 3136871
doi: 10.1002/polb.22259
Gou, M. et al. Transdermal anaesthesia with lidocaine nano-formulation pretreated with low-frequency ultrasound in rats model. J. Nanosci. Nanotechnol. 9, 6360–6365 (2009).
pubmed: 19908534
doi: 10.1166/jnn.2009.1343
Cohn, D. & Hotovely Salomon, A. Designing biodegradable multiblock PCL/PLA thermoplastic elastomers. Biomaterials 26, 2297–2305 (2005).
pubmed: 15585232
doi: 10.1016/j.biomaterials.2004.07.052
Cutright, D. E., Beasley, J. D. & Perez, B. Histologic comparison of polylactic and polyglycolic acid sutures. Oral. Surg. Oral. Med. Oral. Pathol. 32, 165–173 (1971).
pubmed: 5281553
doi: 10.1016/0030-4220(71)90265-9
Frazza, E. J. & Schmitt, E. E. A new absorbable suture. J. Biomed. Mater. Res. 5, 43–58 (1971).
pubmed: 5575328
doi: 10.1002/jbm.820050207
Lee, J. E. et al. Surgical suture assembled with polymeric drug-delivery sheet for sustained, local pain relief. Acta Biomater. 9, 8318–8327 (2013).
pubmed: 23770220
doi: 10.1016/j.actbio.2013.06.003
Padmakumar, S. et al. Electrospun polymeric core–sheath yarns as drug eluting surgical sutures. ACS Appl. Mater. Interfaces 8, 6925–6934 (2016).
pubmed: 26936629
doi: 10.1021/acsami.6b00874
Ungaro, F. et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Controlled Release. 157, 149–159 (2011).
doi: 10.1016/j.jconrel.2011.08.010
Toti, U. S. et al. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32, 6606–6613 (2011).
pubmed: 21652065
pmcid: 3133877
doi: 10.1016/j.biomaterials.2011.05.038
Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475–2490 (2000).
pubmed: 11055295
doi: 10.1016/S0142-9612(00)00115-0
Fu, K., Pack, D., Klibanov, A. & Langer, R. Visual evidence of acidic environment within degrading Poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17, 100–106 (2000).
pubmed: 10714616
doi: 10.1023/A:1007582911958
Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161, 505–522 (2012).
pubmed: 22353619
doi: 10.1016/j.jconrel.2012.01.043
Kappy, M., Stuart, T., Perelman, A. & Clemons, R. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty. J. Clin. Endocrinol. Metab. 69, 1087–1089 (1989).
pubmed: 2507570
doi: 10.1210/jcem-69-5-1087
Garner, J. et al. A protocol for assay of poly(lactide-co-glycolide) in clinical products. Int. J. Pharmaceutics 495, 87–92 (2015).
doi: 10.1016/j.ijpharm.2015.08.063
Ensign, L. M. et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 4, 138ra179 (2012).
doi: 10.1126/scitranslmed.3003453
Pakulska, M. et al. Encapsulation-free controlled release: electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles. Sci. Adv. 2, e1600519 (2016).
pubmed: 27386554
pmcid: 4928928
doi: 10.1126/sciadv.1600519
Schneider, C. S. et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci. Adv. 3, e1601556 (2017).
pubmed: 28435870
pmcid: 5381952
doi: 10.1126/sciadv.1601556
Tobío, M., Gref, R., Sánchez, A., Langer, R. & Alonso, M. J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 15, 270–275 (1998).
pubmed: 9523314
doi: 10.1023/A:1011922819926
Khodaverdi, E. et al. Preparation and analysis of a sustained drug delivery system by PLGA–PEG–PLGA triblock copolymers. Polym. Bull. 69, 429–438 (2012).
Miyazaki, M. et al. PEG-based nanocomposite hydrogel: thermoresponsive sol-gel transition controlled by PLGA-PEG-PLGA molecular weight and solute concentration. Polymer 115, 246–254 (2017).
De Koker, S., Hoogenboom, R. & De Geest, B. G. Polymeric multilayer capsules for drug delivery. Chem. Soc. Rev. 41, 2867–2884 (2012).
pubmed: 22282265
doi: 10.1039/c2cs15296g
Sarode, A., Annapragada, A., Guo, J. & Mitragotri, S. Layered self-assemblies for controlled drug delivery: a translational overview. Biomaterials 242, 119929 (2020).
pubmed: 32163750
doi: 10.1016/j.biomaterials.2020.119929
Durect:. POSIMIR®(bupivacaine extended-release solution). http://www.durect.com/pipeline/development/posimir/ (2020).
Singla, N. et al. Opioid-free recovery after herniorrhaphy with HTX-011 as the foundation of a multimodal analgesic regimen. Surgery 168, 915–920 (2020).
pubmed: 32943200
doi: 10.1016/j.surg.2020.06.036
Center for Drug Evaluation and Research (CDER). Determining Whether to Submit an ANDA or a 505(b)(2) Application: Guidance for Industry. Docket Number: FDA-2017-D-5974. (U.S. Food & Drug Administration, 2019).
Freije, I., Lamouche, S. & Tanguay, M. Review of drugs approved via the 505(b)(2) pathway: uncovering drug development trends and regulatory requirements. Ther. Innov. Regul. Sci. 54, 128–138 (2020).
pubmed: 32008242
doi: 10.1007/s43441-019-00036-y
McKernan, L. C. et al. Posttraumatic stress symptoms mediate the effects of trauma exposure on clinical indicators of central sensitization in patients with chronic pain. Clin. J. Pain. 35, 385–393 (2019).
pubmed: 30730446
pmcid: 6450707
doi: 10.1097/AJP.0000000000000689
Ji, R. R., Nackley, A., Huh, Y., Terrando, N. & Maixner, W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology 129, 343–366 (2018).
pubmed: 29462012
doi: 10.1097/ALN.0000000000002130
Ji, R.-R., Xu, Z.-Z. & Gao, Y.-J. Emerging targets in neuroinflammation-driven chronic pain. Nat. Rev. Drug Discov. 13, 533–548 (2014).
pubmed: 24948120
pmcid: 4228377
doi: 10.1038/nrd4334
Schumacher, M. A., Basbaum, A. I. & Way, W. Basic and clinical pharmacology. In Opiod Analgesics and Antagonists, 12th edn, 542–543 (McGraw-Hill, 2012).
Ioan, D.-C. et al. Piroxicam-Collagen-Based Sponges for Medical Applications. International Journal of Polymer Science 2019, 1–7 (2019).
Catanzano, O., Docking, R., Schofield, P. & Boateng, J. Advanced multi-targeted composite biomaterial dressing for pain and infection control in chronic leg ulcers. Carbohydrate Polymers 172, 40–48 (2017).
pubmed: 28606546
doi: 10.1016/j.carbpol.2017.05.040
Cohen, B., Shefy-Peleg, A. & Zilberman, M. Novel gelatin/alginate soft tissue adhesives loaded with drugs for pain management: structure and properties. Journal of Biomaterials Science, Polymer Edition 25, 224–240 (2014).
doi: 10.1080/09205063.2013.849904
Shikanov, A., Domb, A. J. & Weiniger, C. F. Long acting local anesthetic-polymer formulation to prolong the effect of analgesia. J Control Release 117, 97–103 (2007).
pubmed: 17137669
doi: 10.1016/j.jconrel.2006.10.014
Wu, M. H. et al. Evaluation of a novel biodegradable thermosensitive keto-hydrogel for improving postoperative pain in a rat model. PLoS One 12, e0186784 (2017).
pubmed: 29059223
pmcid: 5653328
doi: 10.1371/journal.pone.0186784
Li, A., Yang, F., Xin, J. & Bai, X. An efficient and long-acting local anesthetic: ropivacaine-loaded lipid-polymer hybrid nanoparticles for the control of pain. Int. J. Nanomed. 14, 913–920 (2019).
doi: 10.2147/IJN.S190164
Wang, Z. et al. Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats. Int. J. Nanomed. 11, 2081–2090 (2016).
Zhao, C. et al. Polymer-tetrodotoxin conjugates to induce prolonged duration local anesthesia with minimal toxicity. Nat. Commun. 10, 2566 (2019).
pubmed: 31189915
pmcid: 6561913
doi: 10.1038/s41467-019-10296-9
Chai, F. et al. In vivo evaluation of post-operative pain reduction on rat model after implantation of intraperitoneal PET meshes functionalised with cyclodextrins and loaded with ropivacaine. Biomaterials 192, 260–270 (2019).
pubmed: 30458361
doi: 10.1016/j.biomaterials.2018.07.032
Kovaliov, M. et al. Extended-release of opioids using fentanyl-based polymeric nanoparticles for enhanced pain management. RSC Advances 7, 47904–47912 (2017).
doi: 10.1039/C7RA08450A
Tobe, M. et al. Long-term effect of sciatic nerve block with slow-release lidocaine in a rat model of postoperative pain. Anesthesiology 112, 1473–1481 (2010).
pubmed: 20461003
doi: 10.1097/ALN.0b013e3181d4f66f
Liu, K. S., Chen, W. H., Lee, C. H., Su, Y. F. & Liu, S. J. Extended pain relief achieved by analgesic-eluting biodegradable nanofibers in the Nuss procedure: in vitro and in vivo studies. Int. J. Nanomed. 13, 8355–8364 (2018).
doi: 10.2147/IJN.S189505
Petit, A. et al. Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomaterials 35, 7919–7928 (2014).
pubmed: 24952978
doi: 10.1016/j.biomaterials.2014.05.064
Lee, K. J., Yang, S. Y. & Ryu, W. Controlled release of bupivacaine HCl through microchannels of biodegradable drug delivery device. Biomed. Microdevices. 14, 583–593 (2012).
pubmed: 22374474
doi: 10.1007/s10544-012-9637-8
Abid, S., Hussain, T., Nazir, A., Zahir, A. & Khenoussi, N. A novel double-layered polymeric nanofiber-based dressing with controlled drug delivery for pain management in burn wounds. Polymer Bulletin 76, 6387–6411 (2019).
doi: 10.1007/s00289-019-02727-w
Indulekha, S., Arunkumar, P., Bahadur, D. & Srivastava, R. Thermoresponsive polymeric gel as an on-demand transdermal drug delivery system for pain management. Mater Sci Eng C Mater Biol Appl 62, 113–122 (2016).
pubmed: 26952404
doi: 10.1016/j.msec.2016.01.021
Yue, J. et al. Facile design and development of photoluminescent graphene quantum dots grafted dextran/glycol-polymeric hydrogel for thermoresponsive triggered delivery of buprenorphine on pain management in tissue implantation. J Photochem Photobiol B 197, 111530 (2019).
pubmed: 31279287
doi: 10.1016/j.jphotobiol.2019.111530